JP2010070573A5 - - Google Patents

Download PDF

Info

Publication number
JP2010070573A5
JP2010070573A5 JP2009295495A JP2009295495A JP2010070573A5 JP 2010070573 A5 JP2010070573 A5 JP 2010070573A5 JP 2009295495 A JP2009295495 A JP 2009295495A JP 2009295495 A JP2009295495 A JP 2009295495A JP 2010070573 A5 JP2010070573 A5 JP 2010070573A5
Authority
JP
Japan
Prior art keywords
changes
neurotransmitters
pain
depression
relationship
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009295495A
Other languages
English (en)
Other versions
JP2010070573A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010070573A publication Critical patent/JP2010070573A/ja
Publication of JP2010070573A5 publication Critical patent/JP2010070573A5/ja
Pending legal-status Critical Current

Links

Description

図１は、神経伝達物質の変化と、鬱病と、神経内分泌の変化と、睡眠障害と 、疼痛との間の関係の模式図である。
JP2009295495A 2002-04-24 2009-12-25 ストレス関連障害を含む機能的身体障害の予防および処置 Pending JP2010070573A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37506802P 2002-04-24 2002-04-24
US46428803P 2003-04-18 2003-04-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003587377A Division JP2005523334A (ja) 2002-04-24 2003-04-24 ストレス関連障害を含む機能的身体障害の予防および処置

Publications (2)

Publication Number Publication Date
JP2010070573A JP2010070573A (ja) 2010-04-02
JP2010070573A5 true JP2010070573A5 (ja) 2011-02-10

Family

ID=29273017

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003587377A Withdrawn JP2005523334A (ja) 2002-04-24 2003-04-24 ストレス関連障害を含む機能的身体障害の予防および処置
JP2009295495A Pending JP2010070573A (ja) 2002-04-24 2009-12-25 ストレス関連障害を含む機能的身体障害の予防および処置

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003587377A Withdrawn JP2005523334A (ja) 2002-04-24 2003-04-24 ストレス関連障害を含む機能的身体障害の予防および処置

Country Status (8)

Country Link
US (2) US20030232805A1 (ja)
EP (1) EP1499309A4 (ja)
JP (2) JP2005523334A (ja)
CN (1) CN1662231A (ja)
AU (1) AU2003225206B2 (ja)
CA (1) CA2483093A1 (ja)
MX (1) MXPA04011529A (ja)
WO (1) WO2003090743A1 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
TW200402289A (en) * 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
EP1513510A1 (en) * 2002-05-30 2005-03-16 Head Explorer A/S The use of milnacipran for the treatment of tension-type headache
AU2003284005B2 (en) * 2002-10-03 2009-12-17 Forest Laboratories Holdings Limited Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
EP1565182A1 (en) * 2002-11-19 2005-08-24 Eli Lilly And Company Treatment of gastrointestinal disorders with duloxetine
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
WO2004075886A1 (fr) * 2003-02-14 2004-09-10 Pierre Fabre Medicament Utilisation de l’enantiomere (1s, 2r) du milnacipran pour la preparation d’un medicament
EP1644004A4 (en) * 2003-06-20 2010-10-06 Ronald Aung-Din LOCAL THERAPY FOR THE TREATMENT OF MIGRAINS, MUSCLE CLARIFICATIONS, MUSCLE SPASMS, SPASTICITY AND RELATED CONDITIONS
EP1667686A1 (en) * 2003-09-09 2006-06-14 Pfizer Products Inc. Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
EP1675582A1 (en) * 2003-09-12 2006-07-05 Warner-Lambert Company LLC Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders
CA2611724C (en) * 2005-06-10 2014-07-29 Pierre Fabre Medicament S.A. Stabilized milnacipran formulation
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
MX2010000937A (es) * 2007-07-23 2010-06-25 Synosia Therapeutics Inc Tratamiento del trastorno por estrés postraumático.
US20100040680A1 (en) * 2008-08-15 2010-02-18 Felix Lai Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation
CA2779711C (en) 2009-11-06 2016-11-01 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
FR2978350B1 (fr) 2011-07-28 2013-11-08 Pf Medicament Medicament a base de levomilnacipran pour la rehabilitation fonctionnelle apres accident neurologique aigu
WO2017087691A1 (en) 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
AU2020259406A1 (en) 2019-04-17 2021-11-04 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
JP2023509800A (ja) * 2020-01-10 2023-03-09 コンシナンス セラピューティクス， インコーポレイテッド 薬物の治療的組み合わせ及びそれらの使用方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2508035A1 (fr) * 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
AU4542893A (en) * 1992-06-23 1994-01-24 Sepracor, Inc. Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
US5352683A (en) * 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
WO1995022521A1 (fr) * 1994-02-22 1995-08-24 Asahi Kasei Kogyo Kabushiki Kaisha Derive d'aminoalkylcyclopropane
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
CN1494907A (zh) * 1996-03-25 2004-05-12 治疗疼痛的药物组合物
EP0906104A4 (en) * 1996-03-25 2003-12-10 Lilly Co Eli PAIN TREATMENT PROCESS
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
US6284794B1 (en) * 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
AU7472898A (en) * 1997-05-07 1998-11-27 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
US6066643A (en) * 1997-10-17 2000-05-23 Eli Lilly And Company Potentiation of pharmaceuticals
CA2337507A1 (en) * 1998-07-16 2000-01-27 Massachusetts Institute Of Technology Composition for treatment of stress
SI1113797T1 (sl) * 1998-09-15 2010-02-26 Lilly Co Eli Uporaba duloksetina pri zdravljenju fibromialgije
CA2348281A1 (en) * 1998-10-27 2000-05-04 Donald W. Landry Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof
WO2000028980A2 (en) * 1998-11-13 2000-05-25 Eli Lilly And Company Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain
US6323242B1 (en) * 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
SK286669B6 (sk) * 1999-07-01 2009-03-05 Pharmacia & Upjohn Company Použitie opticky čistého (S,S)-reboxetínu alebo jeho farmaceuticky prijateľnej soli na výrobu lieku na liečenie alebo prevenciu periférnej neuropatie
HU229295B1 (en) * 1999-08-04 2013-10-28 Astellas Pharma Inc Stable medicinal compositions for oral use
CA2380373A1 (en) * 1999-08-13 2001-02-22 Seth Lederman Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof
AP2002002501A0 (en) * 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
CA2364211A1 (en) * 2000-12-05 2002-06-05 Phillip Branch Chappell Combination treatment for depression, anxiety and psychosis
CA2431041A1 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
US20020147196A1 (en) * 2001-04-05 2002-10-10 Quessy Steven Noel Composition and method for treating neuropathic pain
CA2444053C (en) * 2001-04-19 2008-06-17 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
AU2003213009A1 (en) * 2002-02-12 2003-09-04 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
WO2004045718A2 (en) * 2002-11-20 2004-06-03 Cypress Bioscience, Inc. Treatment of cognitive dysfunctions'

Similar Documents

Publication Publication Date Title
JP2010070573A5 (ja)
JP2012531046A5 (ja)
JP2011528458A5 (ja)
JP2010518805A5 (ja)
JP2010535151A5 (ja)
USD623743S1 (en) Orthopedic plate
JP2011100877A5 (ja)
JP2012247472A5 (ja)
JP2012523912A5 (ja)
JP2008517002A5 (ja)
JP2012099199A5 (ja)
JP2013513924A5 (ja)
JP2010151225A5 (ja)
JP2011034125A5 (ja)
CN301023331S (zh) 取汁机
CN300781329S (zh) 公交车车身(a)
CN301232455S (zh) 感应垃圾桶（dzt-49-18）
CN301252802S (zh) 感应垃圾桶（dzt-50-20）
CN301044681S (zh) 调色机
CN301245525S (zh) 客车车身
CN300965425S (zh) 电源机柜(1)
CN300809668S (zh) 电源设备
CN300795075S (zh) 生物芯片杂交仪
CN300837064S (zh) 摩托车(骏旅)
CN301199831S (zh) 滑模摊铺机